See What HealthDay Can Do For You
Contact Us

Prostate Cancer Combination Therapy Affects Quality of Life

Hormonal therapy after iodine-125 brachytherapy found to impair urinary and sexual function

FRIDAY, July 28 (HealthDay News) -- Neoadjuvant hormonal therapy (NHT) may adversely affect the quality of life in prostate cancer patients who are treated with permanent iodine-125 brachytherapy (BT), according to a study published in the July issue of Urology.

Michael Pinkawa, M.D., of RWTH Aachen University in Aachen, Germany, and colleagues compared quality-of-life scores and symptom rates in 134 prostate cancer patients who underwent NHT and BT and 111 controls with similar demographic characteristics who were not treated for prostate cancer.

A month after implantation, the researchers found that prostatic edema was common in the NHT-BT group but barely detectable in the BT-only group. They also found that the NHT-BT group had lower overall health-related quality-of-life scores compared with controls and those treated with BT alone. In particular, statistically significant differences of more than 10 points were seen for urinary bother, sexual function/bother and hormonal function/bother.

"The results stress the need for well-considered administration of NHT before BT and the need for reporting the use of NHT in studies dealing with BT-related toxicity," the authors conclude.

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.